Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06510504 · ClinicalTrials.gov registry record · Phase 3
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
A Phase 3 study of Social Anxiety Disorder, sponsored by Bionomics Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 370
- Enrollment target
- 20
- Study locations
NCT06510504 is a Phase 3 study of Social Anxiety Disorder that has completed, run by Bionomics Limited. The registered enrollment target is 370 participants, above the 149-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target (148% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT06510504, a Phase 3 study of Social Anxiety Disorder, has completed, sponsored by Bionomics Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 370 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the effect of a single, acute dose of BNC210 compared to placebo on reducing the severity of anxiety provoked by a behavioral assessment task and measured using the Subjective Units of Distress Scale (SUDS) in adult patients with social anxiety disorder.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG 225 mg BNC210
Study Locations (20)
California
- AFFIRM-1 Study Site - Encino
- AFFIRM-1 Study Site - La Jolla
- AFFIRM-1 Study Site - Los Angeles
- AFFIRM-1 Study Site - Oceanside
- AFFIRM-1 Study Site - San Diego
- AFFIRM-1 Study Site - San Jose
- AFFIRM-1 Study Site - Sherman Oaks
- AFFIRM-1 Study Site - Temecula
Florida
- AFFIRM-1 Study Site - Jacksonville
- AFFIRM-1 Study Site - Lauderhill
- AFFIRM-1 Study Site - Miami Lakes
- AFFIRM-1 Study Site - Orlando
- AFFIRM-1 Study Site - Tampa
Massachusetts
- AFFIRM-1 Study Site - Boston
- AFFIRM-1 Study Site - Boston
Georgia
- AFFIRM-1 Study Site - Decatur
New Jersey
- AFFIRM-1 Study Site - Princeton
New York
- AFFIRM-1 Study Site - Brooklyn
North Carolina
- AFFIRM-1 Study Site - Charlotte
Pennsylvania
- AFFIRM-1 Study Site - Media
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2024-08-06 |
| Est. Completion | 2025-09-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06510504
The ClinicalTrials.gov registry entry for NCT06510504 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 370 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 149-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target (148% higher). The listed sponsor is Bionomics Limited, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Social Anxiety Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06510504 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06510504 about?
NCT06510504 is a clinical study titled "Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1". The purpose of the study is to evaluate the effect of a single, acute dose of BNC210 compared to placebo on reducing the severity of anxiety provoked by a behavioral assessment task and measured using the Subjective Units of Distress Scale (SUDS) in adult patients with social anxiety disorder.
What is the current status of trial NCT06510504?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 370 participants. The study started on 2024-08-06. Estimated completion is 2025-09-19.
What conditions does trial NCT06510504 study?
This clinical trial studies the following conditions: Social Anxiety Disorder.
What interventions are being tested in trial NCT06510504?
The interventions under investigation include: Placebo (DRUG), 225 mg BNC210 (DRUG).
Who is sponsoring clinical trial NCT06510504?
This trial is sponsored by Bionomics Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06510504 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
RECRUITING · Phase 3
-
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
ACTIVE NOT RECRUITING · Phase 3
-
Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder
COMPLETED · Phase 3
-
Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety
COMPLETED · Phase 3
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Individual Factors of CBT Underlying Success
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.